Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

Dow Jones

Oct 07, 2024

By Don Nico Forbes

Shares in Liquidia rose after the U.S. Supreme Court rejected an appeal by United Therapeutics in the fellow biotech company's patent dispute.

Shares were recently up 12% at $11.20.

The court rejected United's appeal over a decision to invalidate its patent claims concerning Liquidia's drug Yutrepia, with the decision now final and not subject to further appeal, Liquidia said.

United claims the drug infringes on its patent covering the inhaled administration of the drug treprostinil. Yutrepia is an inhaled version of treprostinil. Liquidia sells treprostinil in pills, powder and injections.

On May 31, a U.S. district court had denied United's request for a preliminary injunction.

The U.S. Food and Drug Administration gave tentative approval for Yutrepia to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in August, the company said. Final approval may occur after the expiration of three-year regulatory exclusivity for Tyvaso DPI on May 23, 2025, it added.

Write to Don Nico Forbes at don.forbes@wsj.com

(END) Dow Jones Newswires

October 07, 2024 10:59 ET (14:59 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2473737104"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2473737104\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2473737104?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-07 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473737104","market":"sg","top_or_hot":-1,"title":"Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Liquidia rose after the U.S. Supreme Court rejected an appeal by United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in the fellow biotech company's patent dispute. \n</p>\n<p>\n  Shares were recently up 12% at $11.20. \n</p>\n<p>\n  The court rejected United's appeal over a decision to invalidate its patent claims concerning Liquidia's drug Yutrepia, with the decision now final and not subject to further appeal, Liquidia said. \n</p>\n<p>\n  United claims the drug infringes on its patent covering the inhaled administration of the drug treprostinil. Yutrepia is an inhaled version of treprostinil. Liquidia sells treprostinil in pills, powder and injections. \n</p>\n<p>\n  On May 31, a U.S. district court had denied United's request for a preliminary injunction. \n</p>\n<p>\n  The U.S. Food and Drug Administration gave tentative approval for Yutrepia to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in August, the company said. Final approval may occur after the expiration of three-year regulatory exclusivity for Tyvaso DPI on May 23, 2025, it added. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2024 10:59 ET (14:59 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-07 22:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Liquidia rose after the U.S. Supreme Court rejected an appeal by United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in the fellow biotech company's patent dispute. \n</p>\n<p>\n  Shares were recently up 12% at $11.20. \n</p>\n<p>\n  The court rejected United's appeal over a decision to invalidate its patent claims concerning Liquidia's drug Yutrepia, with the decision now final and not subject to further appeal, Liquidia said. \n</p>\n<p>\n  United claims the drug infringes on its patent covering the inhaled administration of the drug treprostinil. Yutrepia is an inhaled version of treprostinil. Liquidia sells treprostinil in pills, powder and injections. \n</p>\n<p>\n  On May 31, a U.S. district court had denied United's request for a preliminary injunction. \n</p>\n<p>\n  The U.S. Food and Drug Administration gave tentative approval for Yutrepia to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in August, the company said. Final approval may occur after the expiration of three-year regulatory exclusivity for Tyvaso DPI on May 23, 2025, it added. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2024 10:59 ET (14:59 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2473737104","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473737104","pubTimestamp":1728313140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in Liquidia rose after the U.S. Supreme Court rejected an appeal by United Therapeutics in the fellow biotech company's patent dispute.The court rejected United's appeal over a decision to invalidate its patent claims concerning Liquidia's drug Yutrepia, with the decision now final and not subject to further appeal, Liquidia said.United claims the drug infringes on its patent covering the inhaled administration of the drug treprostinil. Yutrepia is an inhaled version of treprostinil. Liquidia sells treprostinil in pills, powder and injections.On May 31, a U.S. district court had denied United's request for a preliminary injunction.The U.S. Food and Drug Administration gave tentative approval for Yutrepia to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in August, the company said. Final approval may occur after the expiration of three-year regulatory exclusivity for Tyvaso DPI on May 23, 2025, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","UTHR":"美国联合医疗","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4007":"制药"},"translate_title":"最高法院驳回United Therapeutics的专利上诉后，Liquidia股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":0.9,"UTHR":1},"content_text":"By Don Nico Forbes \n\n\n \n\n\n  Shares in Liquidia rose after the U.S. Supreme Court rejected an appeal by United Therapeutics in the fellow biotech company's patent dispute. \n\n\n  Shares were recently up 12% at $11.20. \n\n\n  The court rejected United's appeal over a decision to invalidate its patent claims concerning Liquidia's drug Yutrepia, with the decision now final and not subject to further appeal, Liquidia said. \n\n\n  United claims the drug infringes on its patent covering the inhaled administration of the drug treprostinil. Yutrepia is an inhaled version of treprostinil. Liquidia sells treprostinil in pills, powder and injections. \n\n\n  On May 31, a U.S. district court had denied United's request for a preliminary injunction. \n\n\n  The U.S. Food and Drug Administration gave tentative approval for Yutrepia to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in August, the company said. Final approval may occur after the expiration of three-year regulatory exclusivity for Tyvaso DPI on May 23, 2025, it added. \n\n\n \n\n\n  Write to Don Nico Forbes at don.forbes@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 07, 2024 10:59 ET (14:59 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}